19,968 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Purchased by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 19,968 shares of the biopharmaceutical company's stock, valued at approximately $484,000.

A number of other institutional investors have also recently bought and sold shares of CPRX. Nilsine Partners LLC lifted its stake in Catalyst Pharmaceuticals by 64.8% in the first quarter. Nilsine Partners LLC now owns 55,249 shares of the biopharmaceutical company's stock valued at $1,340,000 after buying an additional 21,730 shares in the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in Catalyst Pharmaceuticals in the first quarter valued at approximately $211,000. CWA Asset Management Group LLC lifted its stake in Catalyst Pharmaceuticals by 30.8% in the first quarter. CWA Asset Management Group LLC now owns 44,081 shares of the biopharmaceutical company's stock valued at $1,069,000 after buying an additional 10,383 shares in the last quarter. Bfsg LLC lifted its stake in Catalyst Pharmaceuticals by 7.8% in the first quarter. Bfsg LLC now owns 161,863 shares of the biopharmaceutical company's stock valued at $3,925,000 after buying an additional 11,733 shares in the last quarter. Finally, Sound Income Strategies LLC bought a new position in Catalyst Pharmaceuticals in the first quarter valued at approximately $64,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Insider Activity

In other news, insider Preethi Sundaram sold 2,324 shares of the stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total value of $61,376.84. Following the transaction, the insider directly owned 42,681 shares of the company's stock, valued at $1,127,205.21. This represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary Ingenito sold 200,000 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the completion of the transaction, the insider directly owned 68,873 shares in the company, valued at $1,630,912.64. The trade was a 74.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 247,924 shares of company stock worth $5,879,369 over the last three months. Insiders own 10.40% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Six investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of "Buy" and an average price target of $32.83.

Catalyst Pharmaceuticals Stock Down 0.2%

Shares of CPRX traded down $0.04 during trading hours on Friday, hitting $21.81. The company had a trading volume of 1,402,938 shares, compared to its average volume of 1,134,850. The firm has a market cap of $2.66 billion, a price-to-earnings ratio of 13.89, a PEG ratio of 0.89 and a beta of 0.66. The business has a fifty day moving average of $23.45 and a 200-day moving average of $22.89. Catalyst Pharmaceuticals, Inc. has a 12 month low of $15.34 and a 12 month high of $26.58.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.